News

Public · Published

Eisai to Present New Five-Year Lecanemab Data and Real-World Alzheimer's Disease Research at the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference

Eisai announced it will present new Alzheimer's disease research at the November 16–19, 2026 CTAD conference in Boston and online. The program includes five-year lecanemab treatment findings from the Clarity AD study, real-world data from the LEADER study, one symposium, five oral presentations and 19 posters.

Published:

Updated:

What happened

Eisai announced it will present new Alzheimer’s disease research at the November 16–19, 2026 CTAD conference in Boston and online. The program includes five-year lecanemab treatment findings from the Clarity AD study, real-world data from the LEADER study, one symposium, five oral presentations and 19 posters.

Confirmed

Global impact / market context

The presentations could shape views of lecanemab’s longer-term outcomes and use in routine care. If the findings support continued use, they may strengthen the case for treatment and influence future prescribing; evidence of safety issues or limited benefit could instead constrain demand and affect Eisai’s revenue prospects.

Analyst inference

The announcement sets out planned research presentations, not results or a change in treatment guidance. Investors therefore have no new outcome data in this article to assess yet; the five-year study findings and real-world experience are potential evidence about durability and practical use, not confirmed commercial gains.

Analyst inference

What to watch

  1. At CTAD, look for the actual five-year Clarity AD findings, including what they say about outcomes over time; the article provides no results yet. Confirmed
  2. Review the LEADER analyses for how lecanemab is used across diverse US treatment centers and whether practical use raises safety or access concerns. Proposed
  3. Compare reported long-term outcomes and real-world use: evidence of sustained benefit could support prescribing, while safety concerns or limited benefit could weaken demand. Analyst inference

Evidence

  • Original source link unavailable